These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23425181)

  • 1. Intravenous immune globulin in autoimmune and inflammatory diseases.
    Gelfand EW
    N Engl J Med; 2013 Feb; 368(8):777. PubMed ID: 23425181
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravenous immune globulin in autoimmune and inflammatory diseases.
    Shimoni Z; Bulvik S; Froom P
    N Engl J Med; 2013 Feb; 368(8):776-7. PubMed ID: 23425182
    [No Abstract]   [Full Text] [Related]  

  • 3. Intravenous immune globulin in autoimmune and inflammatory diseases.
    Gelfand EW
    N Engl J Med; 2012 Nov; 367(21):2015-25. PubMed ID: 23171098
    [No Abstract]   [Full Text] [Related]  

  • 4. The use of intravenous immunoglobulin in autoimmune bullous diseases.
    Chee SN; Murrell DF
    Immunol Allergy Clin North Am; 2012 May; 32(2):323-30, viii. PubMed ID: 22560145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update.
    Czernik A; Toosi S; Bystryn JC; Grando SA
    Autoimmunity; 2012 Feb; 45(1):111-8. PubMed ID: 21923613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immunoglobulin in autoimmune and inflammatory dermatoses. A review of proposed mechanisms of action and therapeutic applications.
    Colsky AS
    Dermatol Clin; 2000 Jul; 18(3):447-57, ix. PubMed ID: 10943540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous immunity and autoimmunity.
    Alam R
    Immunol Allergy Clin North Am; 2012 May; 32(2):xi-xii. PubMed ID: 22560147
    [No Abstract]   [Full Text] [Related]  

  • 8. High-dose intravenous immunoglobulin co-treatment prolongs time-to-treatment escalation in autoimmune bullous diseases: A monocentric retrospective cohort study.
    Bertlich M; Bertlich I; Plümacher N; Hadaschik E; Enk A; Hoffmann JHO
    J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e74-e76. PubMed ID: 37595621
    [No Abstract]   [Full Text] [Related]  

  • 9. High-dose intravenous immune globulin is also effective in linear IgA disease.
    Kroiss MM; Vogt T; Landthaler M; Stolz W
    Br J Dermatol; 2000 Mar; 142(3):582. PubMed ID: 10777275
    [No Abstract]   [Full Text] [Related]  

  • 10. [Intravenous immunoglobulins in dermatology].
    Nydegger U; Hunziker T
    Ann Dermatol Venereol; 2002; 129(8-9):1078-81. PubMed ID: 12442118
    [No Abstract]   [Full Text] [Related]  

  • 11. High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases.
    Ishii N; Hashimoto T; Zillikens D; Ludwig RJ
    Clin Rev Allergy Immunol; 2010 Apr; 38(2-3):186-95. PubMed ID: 19557317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulin G in the treatment of autoimmune bullous disease.
    Czernik A
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):118-9. PubMed ID: 25546786
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of autoimmune blistering diseases.
    Levy M; Rico MJ
    Dermatol Clin; 1999 Apr; 17(2):431-40, x. PubMed ID: 10327307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practice and Educational Gaps in Blistering Disease.
    Ehsani-Chimeh N; Marinkovich MP
    Dermatol Clin; 2016 Jul; 34(3):251-6. PubMed ID: 27363880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in the treatment of autoimmune mucocutaneous blistering diseases.
    Ahmed AR
    Int J Periodontics Restorative Dent; 2007 Aug; 27(4):309-10. PubMed ID: 17726986
    [No Abstract]   [Full Text] [Related]  

  • 16. Coverage of Intravenous Immunoglobulin for Autoimmune Blistering Diseases Among US Insurers.
    Valdebran M; Amber KT
    JAMA Dermatol; 2017 Nov; 153(11):1189-1190. PubMed ID: 28813559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of intravenous immunoglobulin in autoimmune bullous diseases.
    Chee SN; Murrell DF
    Dermatol Clin; 2011 Oct; 29(4):565-70. PubMed ID: 21924999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoimmune bullous diseases in childhood.
    Sansaricq F; Stein SL; Petronic-Rosic V
    Clin Dermatol; 2012; 30(1):114-27. PubMed ID: 22137235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: Facts and controversies.
    Schiavo AL; Puca RV; Ruocco V; Ruocco E
    Clin Dermatol; 2010; 28(3):337-43. PubMed ID: 20541689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases.
    Yu Z; Lennon VA
    N Engl J Med; 1999 Jan; 340(3):227-8. PubMed ID: 9895405
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.